Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (20 quarters reported)
$122M in Q4 2013 → — now. Hover for any quarter.
As reported for the quarter ended September 30, 2018. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| N None | NaN% | New | 0 | — |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2018 · filed October 31, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Merck & Co Inc | Exited | −107,434 | −$6.52M | — |
| S Sanofi | Exited | −76,836 | −$3.07M | — |
| MN Mylan N V | Exited | −83,370 | −$3.01M | — |
| CC Cigna Corporation | Exited | −17,392 | −$2.96M | — |
| Astrazeneca PLC | Exited | −71,400 | −$2.51M | — |
| Regeneron Pharmaceuticals | Exited | −5,220 | −$1.8M | — |
| RH Radius Health Inc | Exited | −60,521 | −$1.78M | — |
| Gilead Sciences Inc | Exited | −22,300 | −$1.58M | — |
| Cvs Health Corp | Exited | −24,330 | −$1.57M | — |
| AP Allergan PLC | Exited | −8,723 | −$1.45M | — |
Showing the 10 largest of 26 changes.
quarter ended June 30, 2018 · filed August 13, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Astrazeneca PLC | Trimmed | −686,310 | −$24.1M | 7.2% |
| Exact Sciences Corp | Exited | −541,900 | −$21.9M | — |
| Regeneron Pharmaceuticals | Trimmed | −56,500 | −$19.5M | 5.2% |
| S Sanofi | Trimmed | −434,610 | −$17.4M | 8.9% |
| Pfizer Inc | Exited | −435,360 | −$15.5M | — |
| MN Mylan N V | Trimmed | −410,450 | −$14.8M | 8.7% |
| AP Allergan PLC | Trimmed | −83,649 | −$13.9M | 4.2% |
| Medtronic PLC | Exited | −159,850 | −$12.8M | — |
| CC Cigna Corporation | Trimmed | −74,408 | −$12.6M | 8.5% |
| AB Alder Biopharmaceuticals Inc | Trimmed | −737,332 | −$11.7M | 3.9% |
Showing the 10 largest of 38 changes.
quarter ended March 31, 2018 · filed May 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Astrazeneca PLC | New | +757,710 | +$26.5M | 8.4% |
| Exact Sciences Corp | Added | +536,359 | +$21.6M | 6.9% |
| S Sanofi | Trimmed | −488,340 | −$19.6M | 6.5% |
| Regeneron Pharmaceuticals | Trimmed | −51,780 | −$17.8M | 6.7% |
| AL Abbott Labs | Exited | −307,400 | −$17.5M | — |
| AN Aetna Inc New | Trimmed | −96,300 | −$16.3M | 2.3% |
| Pfizer Inc | New | +435,360 | +$15.5M | 4.9% |
| CC Cigna Corporation | New | +91,800 | +$15.4M | 4.9% |
| Merck & Co Inc | New | +282,420 | +$15.4M | 4.9% |
| AP Allergan PLC | Exited | −25,000 | −$14.7M | — |
Showing the 10 largest of 41 changes.
quarter ended December 31, 2017 · filed February 13, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Exact Sciences Corp | Trimmed | −652,459 | −$137M | 0.3% |
| Halozyme Therapeutics Inc | Trimmed | −3,292,690 | −$66.7M | 2.8% |
| T Tesaro Inc | Exited | −219,500 | −$28.3M | — |
| MN Mylan N V | New | +606,500 | +$25.7M | 6.6% |
| AN Aetna Inc New | New | +140,200 | +$25.3M | 6.5% |
| A Anthem Inc | Exited | −126,700 | −$24.1M | — |
| Cvs Health Corp | New | +315,500 | +$22.9M | 5.8% |
| AL Abbott Labs | New | +307,400 | +$17.5M | 4.5% |
| NA Novartis A G | New | +204,900 | +$17.2M | 4.4% |
| H Healthsouth Corp | Trimmed | −343,300 | −$17M | 1.5% |
Showing the 10 largest of 39 changes.
quarter ended September 30, 2017 · filed November 13, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| S Sanofi | New | +797,486 | +$39.7M | 9.7% |
| MN Mylan N V | Exited | −907,100 | −$35.2M | — |
| Regeneron Pharmaceuticals | New | +77,300 | +$34.6M | 8.4% |
| Neurocrine Biosciences Inc | Exited | −749,200 | −$34.5M | — |
| LE Lilly Eli & Co | Exited | −415,200 | −$34.2M | — |
| ES Express Scripts Hldg Co | Trimmed | −532,400 | −$33.7M | 1.7% |
| AP Allergan PLC | New | +43,600 | +$32.2M | 7.9% |
| T Tesaro Inc | New | +219,500 | +$28.3M | 6.9% |
| Exact Sciences Corp | New | +658,000 | +$27.1M | 6.6% |
| Gilead Sciences Inc | Exited | −373,800 | −$26.5M | — |
Showing the 10 largest of 40 changes.
quarter ended June 30, 2017 · filed August 11, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| S Sanofi | Exited | −1,538,908 | −$69.6M | — |
| Neurocrine Biosciences Inc | New | +749,200 | +$34.5M | 8.5% |
| LE Lilly Eli & Co | New | +415,200 | +$34.2M | 8.4% |
| MN Mylan N V | Added | +690,400 | +$26.8M | 8.7% |
| AP Aerie Pharmaceuticals Inc | New | +391,400 | +$20.6M | 5.1% |
| B Bioverativ Inc | Exited | −343,800 | −$18.7M | — |
| Cvs Health Corp | New | +226,600 | +$18.2M | 4.5% |
| Davita Inc | New | +258,800 | +$16.8M | 4.1% |
| Mimedx Group Inc | Exited | −1,692,850 | −$16.1M | — |
| GM Globus Med Inc | Exited | −447,100 | −$13.2M | — |
Showing the 10 largest of 35 changes.
quarter ended March 31, 2017 · filed May 12, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| LE Lilly Eli & Co | Exited | −547,405 | −$40.3M | — |
| SP Shire PLC | Exited | −196,400 | −$33.5M | — |
| AP Allergan PLC | Exited | −158,700 | −$33.3M | — |
| Halozyme Therapeutics Inc | Added | +2,264,420 | +$29.3M | 11.5% |
| Gilead Sciences Inc | New | +320,600 | +$21.8M | 5.5% |
| T Tesaro Inc | Exited | −142,300 | −$19.1M | — |
| B Bioverativ Inc | New | +343,800 | +$18.7M | 4.7% |
| MP Mallinckrodt Pub Ltd Co | Exited | −306,500 | −$15.3M | — |
| S Sanofi | Added | +304,708 | +$13.8M | 17.6% |
| Tg Therapeutics Inc | New | +1,139,900 | +$13.3M | 3.4% |
Showing the 10 largest of 40 changes.
quarter ended December 31, 2016 · filed February 14, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AP Allergan PLC | Added | +100,200 | +$21M | 8.8% |
| MP Mallinckrodt Pub Ltd Co | New | +306,500 | +$15.3M | 4.0% |
| AN Aetna Inc New | Exited | −123,600 | −$14.3M | — |
| E Endologix Inc | Exited | −1,087,700 | −$13.9M | — |
| Enanta Pharmaceuticals Inc | Exited | −506,900 | −$13.5M | — |
| VP Valeant Pharmaceuticals Intl | Exited | −488,900 | −$12M | — |
| Molina Healthcare Inc | Exited | −179,700 | −$10.5M | — |
| MN Mylan N V | Exited | −273,500 | −$10.4M | — |
| ES Express Scripts Hldg Co | Added | +149,301 | +$10.3M | 8.2% |
| SP Shire PLC | Added | +58,500 | +$9.97M | 8.9% |
Showing the 10 largest of 43 changes.
Loading...
